![]() |
市場調查報告書
商品編碼
1467848
2024-2032 年靜脈治療和靜脈通路市場(按類型、應用、最終用戶和地區)Intravenous Therapy and Vein Access Market by Type, Application, End User, and Region 2024-2032 |
2023 年,全球靜脈 (IV) 治療和靜脈通路市場規模達到 251 億美元。 展望未來, IMARC Group預計到 2032 年,市場規模將達到 382 億美元,2024 年複合年成長率 (CAGR) 為 4.64%。 2032.慢性病盛行率不斷上升、交通事故發生率不斷上升,以及消費者對靜脈注射療法益處的認知不斷提高,是推動市場發展的一些關鍵因素。
靜脈 (IV) 治療是一種醫療程序,涉及透過靜脈將液體、藥物和營養物質直接注射到血液中。此技術通常用於醫院、診所和其他醫療機構來治療各種病症和疾病。靜脈通路是進入靜脈進行靜脈注射治療的過程。醫療保健專業人員通常使用針刺穿皮膚並進入靜脈,由於靜脈細小或受損、脫水和肥胖等因素,這對某些患者來說可能具有挑戰性。靜脈注射療法有多種類型,包括用於脫水的鹽水溶液、用於感染的抗生素以及用於癌症治療的化學治療。除了治療疾病外,靜脈注射療法還可以用於預防措施,例如接種疫苗和維生素。
癌症、糖尿病和自體免疫疾病等慢性病和生活方式疾病的盛行率不斷上升,需要長期用藥和監測,這主要推動了全球靜脈 (IV) 治療和靜脈通路市場的成長。除此之外,道路事故發生率的上升和創傷病例的激增也促進了市場的成長。此外,消費者對靜脈注射治療和靜脈通路益處的認知不斷提高,以及重症監護治療的興起,為市場帶來了有利可圖的成長機會。與此一致的是,對微創手術的偏好的轉變是另一個重要的成長誘導因素。除此之外,醫療保健行業的許多技術進步減少了所需的時間和精力,降低了感染風險並提高了手術的準確性,正在為市場創造積極的前景。同時,對創新療法、藥物和設備的研發(R&D)活動的大量投資也有助於市場擴張。此外,醫療保健支出的增加、醫院數量的增加、家庭醫療保健的廣泛採用以及老年人口的擴大正在加強市場的成長。
The global intravenous (IV) therapy and vein access market size reached US$ 25.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 38.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.64% during 2024-2032. The growing prevalence of chronic diseases, the increasing incidences of road accidents, and the rising consumer awareness about the benefits of IV therapy represent some of the key factors driving the market.
Intravenous (IV) therapy is a medical procedure that involves administering fluids, medications, and nutrition directly into the bloodstream through a vein. This technique is commonly used in hospitals, clinics, and other healthcare facilities to treat various conditions and illnesses. Vein access is the process of entering a vein in order to administer IV therapy. A healthcare professional typically uses a needle to puncture the skin and access a vein, which can be challenging in some patients due to factors such as small or damaged veins, dehydration, and obesity. There are several types of IV therapy, including saline solutions for dehydration, antibiotics for infections, and chemotherapy for cancer treatment. In addition to treating medical conditions, IV therapy can also be used for preventative measures, such as receiving vaccinations and vitamins.
The increasing prevalence of chronic and lifestyle diseases, such as cancer, diabetes, and autoimmune diseases that require long-term medication and monitoring, is primarily driving the global intravenous (IV) therapy and vein access market growth. Besides this, the rising incidences of road accidents and the surging number of trauma cases are contributing to the market growth. Moreover, the escalating consumer awareness about the benefits of IV therapy and vein access and the rise in critical care therapies are presenting remunerative growth opportunities for the market. In line with this, the shifting preference for minimally invasive procedures is acting as another significant growth-inducing factor. In addition to this, numerous technological advancements in the healthcare industry to reduce the needed time and effort, lower the risk of infection, and improve the accuracy of the procedure are creating a positive outlook for the market. Concurrent with this, extensive investments in research and development (R&D) activities for innovating new therapies, drugs, and devices are aiding in market expansion. Furthermore, the increasing healthcare expenditure, rise in the number of hospitals, the widespread adoption of home healthcare, and the expanding geriatric population are strengthening the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global intravenous (IV) therapy and vein access market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, application, and end user.
Implantable Ports
Intravenous Catheters
Hypodermic Needles
Infusion Pumps
Others
The report has provided a detailed breakup and analysis of the intravenous (IV) therapy and vein access market based on the type. This includes implantable ports, intravenous catheters, hypodermic needles, infusion pumps, and others. According to the report, intravenous catheters represented the largest segment.
Nutrition and Buffer Solution
Volume Expander
Medication Administration
Blood Based Products
A detailed breakup and analysis of the intravenous (IV) therapy and vein access market based on the application has also been provided in the report. This includes nutrition and buffer solution, volume expander, medication administration, and blood-based products. According to the report, medication administration accounted for the largest market share.
Hospitals
Ambulatory Surgical Center
Clinics
The report has provided a detailed breakup and analysis of the intravenous (IV) therapy and vein access market based on the end user. This includes hospitals, ambulatory surgical centers, and clinics. According to the report, hospitals represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for intravenous (IV) therapy and vein access. Some of the factors driving the North America intravenous (IV) therapy and vein access market included the growing prevalence of chronic diseases, the increasing number of road accidents, and the expanding geriatric population.
The report has also provided a comprehensive analysis of the competitive landscape in the global intravenous (IV) therapy and vein access market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AngioDynamics Inc., B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, Cardinal Health Inc., Fresenius SE & Co. KGaA, ICU Medical Inc., Medtronic plc, Tekni-Plex Inc., Teleflex Incorporated, Terumo Corporation, Vygon SAS, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.